Valproate and related products contraindicated for pregnant women for prevention of migraine headaches


The FDA ( Food and Drug Administration ) has advised health care professionals and women that the anti-seizure medication Valproate sodium and related products, Valproic acid and Divalproex sodium, are contraindicated and should not be taken by pregnant women for the prevention of migraine headaches.

Based on information from a recent study, there is evidence that these medications can cause decreased IQ ( intelligence quotient ) scores in children whose mothers took them while pregnant. Stronger warnings about use during pregnancy will be added to the drug labels, and Valproate’s pregnancy category for migraine use will be changed from D ( the potential benefit of the drug in pregnant women may be acceptable despite its potential risks ) to X ( the risk of use in pregnant women clearly outweighs any possible benefit of the drug ).

Valproate products will remain in pregnancy category D for treating epilepsy and manic episodes associated with bipolar disorder.

Valproate products are approved for the treatment of certain types of epilepsy, the treatment of manic episodes associated with bipolar disorder, and the prevention of migraine headaches. They are also used off-label ( for uses not approved by FDA ) for other conditions, particularly other psychiatric conditions.

This alert is based on the final results of the Neurodevelopmental Effects of Antiepileptic Drugs ( NEAD ) study showing that children exposed to Valproate products while their mothers were pregnant had decreased IQs at age 6 compared to children exposed to other anti-epileptic drugs.

Recommendation

Valproate products should not be used in pregnant women for prevention of migraine headaches and should be used in pregnant women with epilepsy or bipolar disorder only if other treatments have failed to provide adequate symptom control or are otherwise unacceptable.

Women who are pregnant and taking a Valproate medication should not stop their medication but should talk to their health care professionals immediately. Stopping Valproate treatment suddenly can cause serious and life-threatening medical problems to the woman or her baby. ( Xagena )

Source: FDA, 2013

XagenaMedicine_2013



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved XCopri ( Cenobamate tablets ) to treat partial-onset seizures...


The FDA ( U.S. Food and Drug Administration ) has approved Xcopri ( Cenobamate tablets ) to treat partial-onset seizures...


The positive results of the first pivotal phase 3 study of the investigational medicine Epidiolex ( Cannabidiol or CBD )...


The aim of a study was to evaluate the efficacy and safety of the new antiepileptic drug Brivaracetam ( Briviact...


Brivaracetam ( UCB 34714; Briviact ) is an add-on treatment for adult patients with partial seizures. Similar to Levetiracetam (...


In February 2014, the American Heart Association [ AHA ] /American Stroke Association [ ASA ] released their first guideline...


Preliminary efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with an...


A phase III clinical trial ( Study 332 ) of AMPA receptor antagonist Perampanel ( Fycompa ) has met its...


A study ( Study 307 ) has evaluated safety, tolerability, seizure frequency, and regional variations in treatment responses with the...


Sudden unexpected death in epilepsy ( SUDEP ) is the leading cause of death in people with chronic refractory epilepsy....